Nasdaq · CIK 0001703647
KRRO Korro Bio, Inc.
Insider trading from SEC Form 4. Last filing 27 d ago. Close $10.16 on Oct 9, 2026, +92% from the 52-week low and -80% from the high.
Last 90 days
Net insider value
-$786k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$786k by 2 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
KRROOct 9, 2026 · close 10.16
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Korro Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | Jean Francois Formela director sell | $686k 48,690 shares | -7% | +162% from low-73% from high | |
| 3Weak | Oliver Dolan Senior Vice President, Finance sell | $69 5 shares | -0% | +162% from low-73% from high | |
| 23Weak | Oliver Dolan Senior Vice President, Finance sell | $99k 7,353 shares | -31% | +156% from low-74% from high | |
| 14Weak | Vineet Agarwal Chief Financial Officer sell | $56k 800 shares | -100% | - | |
| 29Weak | Vineet Agarwal Chief Financial Officer sell | $800k 10,216 shares | -100% | - |
Transactions
The last 38 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Jean Francois Formela director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -8,450 | $13.99 | $118k | 672,498 | 27 d ago |
| Sep 11, 2026 | Jean Francois Formela director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,750 | $13.99 | $24k | 139,252 | 27 d ago |
| Sep 14, 2026 | Jean Francois Formela director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -31,888 | $14.12 | $450k | 640,610 | 27 d ago |
| Sep 14, 2026 | Jean Francois Formela director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,602 | $14.12 | $93k | 132,650 | 27 d ago |
| Sep 11, 2026 | Oliver Dolan Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -5 | $13.72 | $69 | 16,241 | 28 d ago |
| Sep 8, 2026 | Oliver Dolan Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -7,347 | $13.51 | $99k | 16,252 | 32 d ago |
| Sep 9, 2026 | Oliver Dolan Senior Vice President, Finance | SOpen-market sale Common Stock10b5-1 | -6 | $13.60 | $82 | 16,246 | 32 d ago |
| Jun 11, 2025 | Nessan Bermingham director | AGrant or award Stock Option (Right to Buy)derivative | +6,010 | $0.00 | $0 | 6,010 | Jun 12, 2025 |
| Jun 11, 2025 | Rachel Meyers director | AGrant or award Stock Option (Right to Buy)derivative | +6,010 | $0.00 | $0 | 6,010 | Jun 12, 2025 |
| Jun 11, 2025 | Timothy R Pearson director | AGrant or award Stock Option (Right to Buy)derivative | +6,010 | $0.00 | $0 | 6,010 | Jun 12, 2025 |
| Jun 11, 2025 | Katharine Knobil director | AGrant or award Stock Option (Right to Buy)derivative | +6,010 | $0.00 | $0 | 6,010 | Jun 12, 2025 |
| Jun 11, 2025 | Jean Francois Formela director | AGrant or award Stock Option (Right to Buy)derivative | +6,010 | $0.00 | $0 | 6,010 | Jun 12, 2025 |
| Jun 11, 2025 | Ali Behbahani director, owner | AGrant or award Stock Option (Right to Buy)derivative | +6,010 | $0.00 | $0 | 6,010 | Jun 12, 2025 |
| Apr 1, 2025 | Oliver Dolan Senior Vice President, Finance | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Apr 1, 2025 |
| Apr 1, 2025 | Loic A Vincent Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Apr 1, 2025 |
| Feb 3, 2025 | Olukemi Olugemo Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +42,000 | $0.00 | $0 | 42,000 | Feb 5, 2025 |
| Feb 3, 2025 | Todd Chappell Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +34,500 | $0.00 | $0 | 34,500 | Feb 5, 2025 |
| Feb 3, 2025 | Ram Aiyar President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 5, 2025 |
| Feb 3, 2025 | Vineet Agarwal Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Feb 5, 2025 |
| Feb 3, 2025 | Jeffrey Cerio General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +29,000 | $0.00 | $0 | 29,000 | Feb 5, 2025 |
| Nov 11, 2024 | Vineet Agarwal Chief Financial Officer | MOption exercise Common Stock10b5-1 | +800 | $11.68 | $9,344 | 800 | Nov 12, 2024 |
| Nov 11, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -800 | $70.00 | $56k | 0 | Nov 12, 2024 |
| Nov 11, 2024 | Vineet Agarwal Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -800 | $0.00 | $0 | 30,807 | Nov 12, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | MOption exercise Common Stock10b5-1 | +9,263 | $11.68 | $108k | 9,263 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | MOption exercise Common Stock10b5-1 | +953 | $14.98 | $14k | 10,216 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -2,023 | $71.51 | $145k | 8,193 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -164 | $73.71 | $12k | 8,029 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -115 | $74.56 | $8,575 | 7,914 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -56 | $76.00 | $4,256 | 7,858 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -23 | $77.00 | $1,771 | 7,835 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -260 | $77.55 | $20k | 7,575 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -457 | $78.59 | $36k | 7,118 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -1,815 | $79.79 | $145k | 5,303 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -4,961 | $80.50 | $399k | 342 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -317 | $81.48 | $26k | 25 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -25 | $82.89 | $2,072 | 0 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,263 | $0.00 | $0 | 31,607 | Oct 18, 2024 |
| Oct 17, 2024 | Vineet Agarwal Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -953 | $0.00 | $0 | 45,594 | Oct 18, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Vineet AgarwalChief Financial Officer
- Ram AiyarPresident and CEO
- Ali Behbahaniowner, director
- Nessan Berminghamdirector
- Jeffrey CerioGeneral Counsel
- Todd ChappellChief Operating Officer
- Oliver DolanSenior Vice President, Finance
- Jean Francois Formeladirector
- Katharine Knobildirector
- Rachel Meyersdirector
- Olukemi OlugemoChief Medical Officer
- Timothy R Pearsondirector
- Loic A VincentChief Scientific Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.